Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance

Clinical Biochemistry

Volumn 45, Issue 10-11, 2012, Pages 787-792

  Gao, Shugui ^a   Hu, Zhenyu ^a   Cheng, Jia ^a   Zhou, Wenhua ^b   Xu, Yongming ^a   Xie, Shuguang ^a   Liu, Shiyan ^a   Li, Zaizhong ^a   Guo, Junming ^b   Dong, Jianyi ^b   Huang, Minfang ^a  

^a Ningbo Kangning Hospital   (China)

^b NINGBO UNIVERSITY   (China)

Author keywords

Polymorphisms; Risperidone; Schizophrenia; Therapeutic response

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; PROLACTIN; RISPERIDONE; VALINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL PATIENT; PLASMA; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; TREATMENT RESPONSE; WECHSLER MEMORY SCALE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; COGNITION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MEMORY; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROLACTIN; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862566587     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.016     Document Type: Article

References (33)

1. Cohen J.D., Servan-Schreiber D. A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr Bull 1993, 19:85-104.
2. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997, 61:75-94.
3. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
4. Karayiorgou M., Simon T.J., Gogos J.A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 2010, 11:402-416.
5. Sagud M., Muck-Seler D., Mihaljevic-Peles A., Vuksan-Cusa B., Zivkovic M., Jakovljevic M., Pivac N., et al. Catechol-O-methyl transferase and schizophrenia. Psychiatr Danub 2010, 22:270-274.
6. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001, 98:6917-6922.
7. Williams H.J., Owen M.J., O'Donovan M.C. Is COMT a susceptibility gene for schizophrenia?. Schizophr Bull 2007, 33:635-641.
8. Eisenberg D.P., Sarpal D., Kohn P.D., Meyer-Lindenberg A., Wint D., Kolachana B., et al. Catechol-o-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia. Biol Psychiatry 2010, 67:287-290.
9. Smolka M.N., Schumann G., Wrase J., Grusser S.M., Flor H., Mann K., et al. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 2005, 25:836-842.
10. Benedetti F., Colombo C., Pirovano A., Marino E., Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2009, 203:155-160.
11. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., et al. Interaction of COMT Val108/158Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004, 161:1798-1805.
12. Woodward N.D., Jayathilake K., Meltzer H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007, 90:86-96.
13. Yamanouchi Y., Iwata N., Suzuki T., Kitajima T., Ikeda M., Ozaki N. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003, 3:356-361.
14. Illi A., Kampman O., Hanninen K., Anttila S., Mattila K.M., Katila H., et al. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum Psychopharmacol 2007, 22:211-215.
15. Chen M.L., Chen C.H. Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. J Psychiatr Res 2007, 41:57-62.
16. Hansenne M. The p300 cognitive event-related potential. II. Individual variability and clinical application in psychopathology. Neurophysiol Clin 2000, 30(4):211.
17. Katsanis J., Iacono W.G., McGue M.K., Carlson S.R. P300 event-related potential heritability in monozygotic and dizygotic twins. Psychophysiology 1997, 34(1):47-58.
18. Hall M.H., Schulze K., Rijsdijk F., Picchioni M., Ettinger U., Bramon E., et al. Heritability and reliability of P300, P50 and duration mismatch negativity. Behav Genet 2006, 36(6):845-857.
19. Bestelmeyer P., Phillips L.H., Crombie C., Benson P., St Clair D. The P300 as a possible endophenotype for schizophrenia and bipolar disorder: evidence from twin and patient studies. Psychiatry Res 2009, 169(3):212-219.
20. Kang C., Xu X., Liu H., Yang J. Association study of catechol-O-methyltransferase (COMT) gene Val158Met polymorphism with auditory P300 in Chinese Han patients with schizophrenia. Psychiatry Res 2010, 180(2-3):153-155.
21. Findling R.L., Kusumakar V., Daneman D., Moshang T., De Smedt G., Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003, 64:1362-1369.
22. David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000, 22:1085-1096.
23. Gupta M., Bhatnagar P., Grover S., Kaur H., Baghel R., Bhasin Y., et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009, 10:385-397.
24. Wang Y., Fang Y., Shen Y., Xu Q. Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res 2010, 179:147-150.
25. Barnett J.H., Heron J., Goldman D., Jones P.B., Xu K. Effects of catechol-O-methyltransferase on normal variation in the cognitive function of children. Am J Psychiatry 2009, 166:909-916.
26. Prata D.P., Mechelli A., Fu C.H., Picchioni M., Kane F., Kalidindi S., et al. Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. Biol Psychiatry 2009, 65:473-480.
27. Barnett J.H., Scoriels L., Munafo M.R. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008, 64:137-144.
28. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-255.
29. Harvey P.D., Hassman H., Mao L., Gharabawi G.M., Mahmoud R.A., Engelhart L.M. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry 2007, 68:1186-1194.
30. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 2008, 28:8709-8723.
31. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60:681-690.
32. Yasui-Furukori N., Saito M., Tsuchimine S., Nakagami T., Sato Y., Sugawara N., et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1491-1495.
33. Dickson R.A., Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999, 35:S75-S86. (Suppl.).